Vorinostat is a histone deacetylase (HDAC) inhibitor that was approved by the US Food and Drug Administration for the treatment of cutaneous T cell lymphoma. This evidence concerns the gene HDAC9 and primary cutaneous T-cell non-Hodgkin lymphoma.